Anacor Co-Founders Recognized for Scientific Achievements
`
`Palo Alto, Calif. - June 10, 2009 - Anacor Pharmaceuticals today congratulates its co-founders and board members, Stephen
`Benkovic and Lucy Shapiro, as the recipients of two of the most prestigious awards given in science. The awards recognize
`their groundbreaking achievements in advancing medical research.
`
`Benjamin Franklin Medal in Life Sciences:
`
`l Stephen Benkovic, Ph.D., Evan Pugh Professor and Eberly Chair in Chemistry at the Pennsylvania State University
`
`Gairdner International Award:
`
`l Lucy Shapiro, Ph.D., Virginia and D.K. Ludwig Professor of Cancer Research and Director of the Beckman Center in the
`School of Medicine at Stanford University
`
`"Steve and Lucy founded Anacor on the basis of their research showing that boron containing small molecules had the
`potential to be important new antibiotics. With their continued scientific contributions and guidance, we've expanded the
`applications of boron chemistry and introduced five internally developed, boron containing molecules into clinical trials," said
`David Perry, Chief Executive Officer of Anacor Pharmaceuticals. "Their contributions to Anacor have been invaluable. On
`behalf of all of the employees of Anacor, I offer our sincere congratulations to both of them."
`
`Stephen Benkovic, Ph.D., is the Evan Pugh Professor and Eberly Chair in Chemistry at the Pennsylvania State University. Dr.
`Benkovic has received a number of awards and fellowships including the Alfred P. Sloan Fellowship, NIH Career Development
`Award, Guggenheim Fellowship, Pfizer Award in Enzyme Chemistry, Arthur C. Cope Scholar Award, Gowland Hopkins Award,
`Alfred Bader Award, Pioneer Award from the American Institute of Chemists and Repligen Award for Chemistry of Biological
`Processes. He is a member of the American Academy of Arts and Sciences, the National Academy of Science, the Institute of
`Medicine and the American Philosophical Society. He received a B.S. and an A.B. from Lehigh University, and a Ph.D. in
`organic chemistry from Cornell University.
`
`Lucy Shapiro, Ph.D., is the Virginia and D.K. Ludwig Professor of Cancer Research and Director of the Beckman Center in the
`School of Medicine at Stanford University. Dr. Shapiro is a Fellow of the American Association for the Advancement of Sciences
`and has been elected to the National Academy of Sciences, the American Academy of Microbiology, the American Academy of
`Arts and Sciences and the Institute of Medicine of the National Academy of Sciences for her work in the fields of molecular
`biology and microbiology. She was elected to the American Philosophical Society and received the Selman Waksman Award
`from the National Academy of Sciences in 2005. She was a non-executive director of GlaxoSmithKline from 2001 to 2006 and is
`on the board of Gen-Probe, Incorporated. She received a B.S. from Brooklyn College and a Ph.D. in molecular biology from the
`Albert Einstein School of Medicine.
`
`Benjamin Franklin Medal in Life Sciences
`The Franklin Institute Awards are among the oldest and most prestigious comprehensive science awards in the world. The
`Franklin Institute Awards identify individuals whose great innovation has benefited humanity, advanced science, launched new
`fields of inquiry, and deepened our understanding of the universe.
`
`Gairdner International Award
`Considered to be one of the most prestigious awards in biomedical science, the prize is given by the Toronto-based Gairdner
`Foundation to honor individuals who have made outstanding and original contributions to medical research.
`
`About Anacor Pharmaceuticals
`Anacor is a biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry
`platform. Anacor has focused initially on developing topical applications of its compounds to treat fungal, bacterial and
`inflammatory diseases. In addition, the Company is developing systemic antiviral and antibacterial therapeutics under a
`research and development agreement with GlaxoSmithKline. Anacor's most advanced product candidate is AN2690, a novel
`topical antifungal in development for the treatment of toenail onychomycosis, which is a fungal infection of the nail and nail bed.
`AN2690 is licensed to Schering-Plough Corporation under a worldwide development and commercialization agreement for all
`indications including the treatment of onychomycosis. For more information www.anacor.com.
`
`Forward-Looking Statements
`
`CFAD v. Anacor, IPR2015-01776, CFAD EXHIBIT 1051 - Page 1 of 2
`
`

`
`This press release may contain forward-looking statements that relate to future events and involve known and unknown risks,
`uncertainties and other factors that could cause actual levels of activity, performance or achievement to differ materially from
`those expressed or implied by these forward-looking statements. These statements reflect the views of Anacor as of the date of
`this press release with respect to future events and, except as required by law, it undertakes no obligation to update or revise
`publicly any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this
`press release.
`
`Contact:
`Anne Bowdidge
`Investor Relations
`650-543-7575
`
`CFAD v. Anacor, IPR2015-01776, CFAD EXHIBIT 1051 - Page 2 of 2